Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

Nattakorn Dhiantravan; John Violet; Renu Eapen; Omar Alghazo; Mark Scalzo; Price Jackson; Simon P Keam; Catherine Mitchell; Paul J Neeson; Shahneen Sandhu; Scott G Williams; Daniel Moon; Nathan Lawrentschuk; Arun Azad; Michael S Hofman; Declan G Murphy

doi:10.1016/j.euf.2020.09.021

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of ¹⁷⁷Lu-PSMA-617 Prior to Prostatectomy

Eur Urol Focus. 2021 Mar;7(2):234-237. doi: 10.1016/j.euf.2020.09.021. Epub 2020 Nov 7.

Authors

Nattakorn Dhiantravan¹, John Violet², Renu Eapen³, Omar Alghazo⁴, Mark Scalzo⁵, Price Jackson⁶, Simon P Keam⁷, Catherine Mitchell⁸, Paul J Neeson⁹, Shahneen Sandhu¹⁰, Scott G Williams², Daniel Moon¹¹, Nathan Lawrentschuk¹², Arun Azad¹⁰, Michael S Hofman¹³, Declan G Murphy¹⁴

Affiliations

¹ Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
² Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
³ Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁴ Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁵ Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁶ Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁷ The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia; Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁸ Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁹ The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia.
¹⁰ Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
¹¹ The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Victoria, Australia.
¹² Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Victoria, Australia.
¹³ Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: michael.hofman@petermac.org.
¹⁴ Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia. Electronic address: declan.murphy@petermac.org.

PMID: 33172774
DOI: 10.1016/j.euf.2020.09.021

Abstract

LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium-177-radiolabelled small molecule PSMA-617 in men with high-risk localised/locoregional advanced prostate cancer with high prostate-specific membrane antigen expression who are undergoing radical prostatectomy and pelvic lymph node dissection.

Publication types

Clinical Trial Protocol
Research Support, Non-U.S. Gov't

MeSH terms

Dipeptides
Heterocyclic Compounds, 1-Ring
Humans
Male
Prostate-Specific Antigen
Prostatectomy*
Prostatic Diseases / surgery*

Substances

Dipeptides
Heterocyclic Compounds, 1-Ring
PSMA-617
Prostate-Specific Antigen